An Overview of Obesity in Children with Psychiatric Disorders Taking Atypical Antipsychotics

REFERENCES

• Casazza K, Ciccazzo M. Improving the dietary patterns of adolescents using a computer-based approach. J Sch Health 2006; 76: 43–6
   PubMed Web of Science ®Google Scholar
• Institute of Medicine. Childhood obesity in the United States: facts and figures. 2005, http://www.iom.edu/Object.File/Master/22/606/FINALfactsandfigures2.pdf
   Google Scholar
• Mack R, Skurnick B, Sterling-Jean Y, Pedra-Nobre M, Bigg D. Fasting insulin levels as a masure of insulin resistance in American blacks. J Appl Res 2004; 4: 90–4
   Google Scholar
• Rao G. Insulin resistance syndrome. Am Fam Physician 2001; 63: 1–7
   Web of Science ®Google Scholar
• Kanai H, Matsuzawa Y, Tokunaga K, et al. Hypertension in obese children: fasting serum insulin levels are closely correlated with blood pressure. Int J Obes 1990; 14: 1047–56
   PubMed Web of Science ®Google Scholar
• Sjoberg R, Nilsson K, Leppert J J. Obesity, shame, and depression in school-aged children: a population-based study. Pediatrics 2005; 116: 389–92
   PubMed Web of Science ®Google Scholar
• Vila G, Zipper E, Dabbas M, et al. Mental disorders in obese children and adolescents. Psychosom Med 2004; 66: 387–94
   PubMed Web of Science ®Google Scholar
• Janssen I, Craig W, Boyce W, Pickett W. Associations between overweight and obesity with bullying behaviors in school-aged children. Pediatrics 2004; 113: 1187–94
   PubMed Web of Science ®Google Scholar
• Allison D, Fontaine K, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999; 60: 215–20
   PubMed Web of Science ®Google Scholar
• Burkart J, Fox R, Rotatori A. Obesity of mentally retarded individuals: prevalence, characteristics, and intervention. Am J Ment Defic 1985; 90: 303–12
   PubMedGoogle Scholar
• Jones B, Basson B, Walker D, Crawford A, Kinon B. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 2001; 62: 41–4
   PubMed Web of Science ®Google Scholar
• Weiden P, McEvoy J. Managing health risks in psychiatric patients: practical clinical interventions. Clin Psychiatry News 2006; 3–11, supp
   Google Scholar
• Tandon R. Jibson. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003; 29: 9–26
   Google Scholar
• Jin H, Meyer J, Jeste D. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002; 14: 59–64
   PubMedGoogle Scholar
• Correll C, Frederickson A, Kane J, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophr Res 2007; 89: 91–100
   PubMed Web of Science ®Google Scholar
• Allison D, Mentore J, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–96
   PubMed Web of Science ®Google Scholar
• Correll C, Penzner J, Parikh U, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am 2006; 15: 177–206
   PubMed Web of Science ®Google Scholar
• Masi G, Mucci M, Millepiedi S. Clozapine in adolescent inpatients with acute mania. J Child Adolesc Psychopharmacol 2002; 12: 93–9
   PubMed Web of Science ®Google Scholar
• Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia. Arch Gen Psychiatry 2006; 63: 721–30
   PubMed Web of Science ®Google Scholar
• Frazier J, Biederman J, Tohen M, et al. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2001; 11: 239–50
   PubMed Web of Science ®Google Scholar
• Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and “high dose” olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. J Biopsychiatry 2008; 63: 524–9
   Google Scholar
• Sikich L, Hamer R, Bashford R, Sheitman B, Lieberman J. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004; 29: 133–45
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick E, Hammerness P, et al. Open-label, 8 week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry 2005; 56: 589–94
   Google Scholar
• Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine vs. placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007; 164: 1547–56
   PubMed Web of Science ®Google Scholar
• Marchand W, Wirth L, Simon C. Quetiapine adjunctive and monotherapy for pediatric bipolar disorder: a retrospective chart review. J Child Adolesc Psychopharmacol 2004; 4: 405–11
   Google Scholar
• DelBello M, Kowatch R, Adler C, et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006; 45: 305–13
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick E, Wozniak J, et al. An open-label trial of risperidone in children and adolescents with bipolar disorder. J. Child Adolesc Psychopharmacol 2005; 15: 311–7
   PubMed Web of Science ®Google Scholar
• Correll C. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry 2007; 46: 687–700
   PubMed Web of Science ®Google Scholar
• Weiden P, Mackell J, McDonnell D. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004; 66: 51–7
   PubMed Web of Science ®Google Scholar
• O'Brien S, Holubkov R, Reis E. Identification, evaluation, and management of obesity in an academic primary care center. Pediatrics 2004; 114: 154–9
   PubMed Web of Science ®Google Scholar
• Littrell K, Hilligoss N, Kirshner C, Petty R, Johnson C. The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh 2003; 35: 237–41
   PubMed Web of Science ®Google Scholar
• Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aus N Z J Psychiatry 2005; 39: 479–86
   PubMed Web of Science ®Google Scholar
• Eliakim A, Friedland O, Kowen G, Wolach B, Nemet D. Parental obesity and higher pre-intervention BMI reduce the likelihood of a multidisciplinary childhood obesity program to succeed—a clinical observation. J Pediatr Endocrinol Metab 2004; 17: 1055–61
   PubMed Web of Science ®Google Scholar
• Diamond G, Siqueland I. Current status of family intervention science. Child Adolesc Psychiatr Clin N Am 2001; 10: 641–61
   PubMed Web of Science ®Google Scholar
• Jiang J, Xia X, Greiner T, Lian G, Rosenqvist U. A two-year family-based behaviour treatment for obese children. Arch Dis Child 2005; 90: 1235–8
   PubMed Web of Science ®Google Scholar
• Vreeland B, Minsky B, Menza M, Radler D, Roemheld-Hamm B, Stern R. A program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv 2003; 54: 1155–7
   PubMed Web of Science ®Google Scholar
• Menza M, Vreeland B, Minsky S, Gara M, Radler D, Sakowitz M. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 2004; 65: 471–7
   PubMed Web of Science ®Google Scholar
• Nemet D, Barkan S, Epstein Y, Friedland O, Kowen G, Eliakin A. Short-and long-term beneficial effects of a combined dietary-behavioral-physical activity intervention for the treatment of childhood obesity. Pediatrics 2005; 115: 443–9
   PubMed Web of Science ®Google Scholar
• O'Keefe C, Noordsy D, Liss T, Weiss H. Reversal of antipsychotic-associated weight gain. J Clin Psychiatry 2003; 64: 907–12
   PubMed Web of Science ®Google Scholar
• Weber M, Wyne K. A Cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophr Res 2006; 83: 95–101
   PubMed Web of Science ®Google Scholar
• Werneke U, Taylor D, Sanders T, Wessely S. Behavioral management of antipsychotic-induced weight gain: a review. Acta Psychiatr Scand 2003; 108: 252–9
   PubMed Web of Science ®Google Scholar
• Faulkner G, Soundy A, Lloyd K. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand 2003; 108: 324–32
   PubMed Web of Science ®Google Scholar
• Kalarchian M, Marcus M, Levine M, et al. Behavioral treatment of obesity in patients taking antipsychotic medications. J Clin Psychiatry 2005; 66: 1058–63
   PubMed Web of Science ®Google Scholar
• Brar J, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2005; 66: 205–12
   PubMed Web of Science ®Google Scholar
• Braet C, Tanghe A, Decaluwe V, Moens E, Rosseel Y. Inpatient treatment for children with obesity: weight loss, psychological well-being, and eating behavior. J Pediatr Psychol 2004; 29: 519–29
   PubMed Web of Science ®Google Scholar
• Carrell A, Clark R, Peterson S, Nemeth B, Sullivan J, Allen D. Improvement of fitness, body composition, and insulin sensitivity in overweight children in a school-based exercise program. Arch Pediatr Adolesc Med 2005; 259: 963–8
   Google Scholar
• Heilbronn L, Jonge L, Frisard M, et al. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals. J Am Med Assoc 2006; 295: 1539–47
   PubMed Web of Science ®Google Scholar
• Cohen S, Glazewski R, Khan S, Khan A. Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. J Clin Psychiatry 2001; 62: 114–6
   PubMed Web of Science ®Google Scholar
• Saris W. Very-low-calorie diets and sustained weight loss. Obes Res 2001; 9: 295–301
   Google Scholar
• Yanovski J. Intensive therapies for pediatric obesity. Pediatr Clin North Am 2001; 48: 1041–53
   PubMed Web of Science ®Google Scholar
• Simons-Morton D, Obarzanek E, Cutler J. Obesity research—limitations of methods, measurements, and medications. JAMA 2006; 295: 826–8
   PubMed Web of Science ®Google Scholar
• Durant N, Cox J. Current treatment approaches to overweight in adolescents. Curr Opin Pediatr 2005; 17: 454–9
   PubMed Web of Science ®Google Scholar
• Gupta S, Masand P, Virk S, et al. Weight decline in patients switching from olanzapine to quetiapine. Schizophr Res 2003; 70: 57–62
   Web of Science ®Google Scholar
• Haan L, Amelsvoort T, Rosien K, Linszen D. Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology 2004; 175: 389–90
   PubMed Web of Science ®Google Scholar
• Daniels S. Pharmacological treatment of obesity in pediatric patients. Pediatr Drugs 2001; 3: 405–10
   PubMedGoogle Scholar
• Molnar D. New drug policy in childhood obesity. Int J Obes 2005; 29: 562–5
   Web of Science ®Google Scholar
• Henness S, Perry C. Orlistat: a review of its use in the management of obesity. Drugs 2006; 66: 1625–56
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Sachse G. The effects of orlistat on body weight and glycemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002; 4: 415–23
   PubMed Web of Science ®Google Scholar
• Muls E, Kolanowski J, Scheen A, Van Gaal L. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled multicenter study. Int J Obes 2001; 25: 1713–21
   PubMed Web of Science ®Google Scholar
• Halpern A, Mancini M, Suplicy H, et al. Latin-American trial of orlistat for weight loss and improvement in glycemic profile in obese diabetic patients. Diabetes Obes Metab 2003; 5: 180–8
   PubMed Web of Science ®Google Scholar
• Krempf M, Louvet J, Allanic H, Miloradovich T, Joubert J, Attall J. Weight reduction and long-term maintenance after 18-month treatment with orlistat for obesity. Int J Obes 2003; 27: 591–7
   PubMed Web of Science ®Google Scholar
• Toplak H, Ziegler O, Keller U, et al. Weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab 2005; 7: 699–708
   PubMed Web of Science ®Google Scholar
• Erdmann J, Lippl F, Klose G, Schusdziarra V. Cholesterol lowering effect of dietary weight loss and orlistat treatment—efficacy and limitations. Aliment Pharmacol Ther 2004; 19: 1173–9
   PubMed Web of Science ®Google Scholar
• Chanoine J, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents. JAMA 2005; 293: 2873–934
   PubMed Web of Science ®Google Scholar
• McDuffie J, Calis K, Uwaifo G, et al. Efficacy of orlistat as an adjunct to behavioral treatment in overweight African-American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab 2004; 17: 307–19
   PubMed Web of Science ®Google Scholar
• McDuffie J, Calis K, Uwaifo G, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002; 10: 642–50
   PubMedGoogle Scholar
• Maahs D, de Serna D, Kolotkin R, et al. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract 2006; 12: 18–28
   PubMedGoogle Scholar
• Poston W, Foreyt J. Sibutramine and the management of obesity. Expert Opin Pharmacother 2004; 5: 633–42
   PubMed Web of Science ®Google Scholar
• Godoy-Matos A, Carraro L, Vieira A, et al. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab 2005; 90: 1460–5
   PubMed Web of Science ®Google Scholar
• Garcia-Morales L, Berber A, Macias-Lara C, Lucio-Ortiz C, Del-Rio-Navaro B E, Dorantes-Alvarez L M. Use of sibutramine in obese Mexican adolescents: a month, randomized, double-blind, placebo-controlled parellel-group trial. Clin Ther 2006; 28: 770–82
   PubMed Web of Science ®Google Scholar
• Violante-Ortiz R, Del-Rio-Navarro B, Lara-Esqueda A, et al. Use of sibutramine in obese Hispanic adolescents. Adv Ther 2005; 22: 642–9
   PubMed Web of Science ®Google Scholar
• Berkowitz R, Wadden T, Tershakovee A, Cronquist J. Behavior therapy and sibutramine for the treatment of adolescent obesity. JAMA 2003; 289: 1805–12
   PubMed Web of Science ®Google Scholar
• Dujovne C, Zavoral J, Rowe E, Mendel C. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am Heart J 2001; 142: 489–97
   PubMed Web of Science ®Google Scholar
• Reisler G, Tauber T, Afriat R, Bortnik O, Goldman M. Sibutramine as an adjuvant therapy in adolescents suffering from morbid besity. Isr Med Assoc J 2006; 8: 30–2
   PubMed Web of Science ®Google Scholar
• Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. Second phase of a double-blind study clinical trial on sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over. Int J Obes 2001; 25: 741–7
   PubMed Web of Science ®Google Scholar
• Henderson D, Copeland P, Daley T, Borba C, Cather C, Nguyen D. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 2005; 162: 954–62
   PubMed Web of Science ®Google Scholar
• Webb E, Viner R. Should metformin be prescribed to overweight adolescents in whom dietary/behavioural modifications have not helped?. Arch Dis Child 2006; 91: 793–4
   PubMed Web of Science ®Google Scholar
• Bridger T, MacDonald S, Baltzer F, Rodd C. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med 2006; 160: 241–6
   PubMedGoogle Scholar
• Glueck C, Aregawi D, Winiarska M, et al. Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab 2006; 19: 831–42
   PubMed Web of Science ®Google Scholar
• Jones K, Arslanian S, Peterokova V, Park J, Tomlinson M. Effect of metformin in pediatric patients with type 2 diabetes. Diabetes Care 2002; 25: 89–94
   PubMed Web of Science ®Google Scholar
• Paolisso G, Amato L, Eccellente R, et al. Effect of metformin on food intake in obese subjects. Eur J Clin Invest 1998; 28: 441–6
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Ambler G, Baur L, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006; 91: 2074–80
   PubMed Web of Science ®Google Scholar
• Kay J, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001; 50: 1457–61
   PubMed Web of Science ®Google Scholar
• Freemark M, Bursey D. The effect of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001; 107: 1–7
   PubMed Web of Science ®Google Scholar
• Morrison J, Cottingham E, Barton B. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002; 159: 655–7
   PubMed Web of Science ®Google Scholar
• Klein D, Cottingham E, Sorter M, Barton B, Morrison J. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006; 163: 2072–9
   PubMed Web of Science ®Google Scholar
• Bray G, Hollander P, Klein S, et al. A 6 month randomized, placebo-controlled dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11: 722–33
   PubMedGoogle Scholar
• Nickel M, Nickel C, Muehlbacher M, et al. Influence of topiramate on olanzapine-related adiposity in women. J Clin Psychopharmachol 2005; 25: 211–7
   PubMed Web of Science ®Google Scholar
• Vieta E, Sanchez-Moreno J, Goikolea J, et al. Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. J Clin Psychopharmacol 2004; 24: 374–8
   PubMed Web of Science ®Google Scholar
• Lin Y, Liu C, Hsiao M. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. Psychiatry Clin Neurosci 2005; 59: 613–5
   PubMed Web of Science ®Google Scholar
• Canitano R. Cllinical Experience with topiramate to counteract neuroleptic-induced weight gain in 10 individuals with autistic spectrum disorders. Brain Dev 2005; 27: 228–32
   PubMed Web of Science ®Google Scholar
• Graham K, Gu H, Lieberman J, Harp J, Perkins D. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with oanzapine. Am J Psychiatry 2005; 162: 1744–6
   PubMed Web of Science ®Google Scholar
• Deberdt W, Winokur A, Cavazzoni P, et al. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol 2005; 15: 13–21
   PubMed Web of Science ®Google Scholar
• Gracious B, Krysiak T, Youngstrom E. Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series. J Child Adolesc Psychopharmacol 2002; 12: 249–57
   PubMed Web of Science ®Google Scholar
• Bahk W, Lee K, Chae J, Pae C, Jun T, Kim K. Open-label study of the effect of amantadine on weight gain induced by olanzapine. Psychiatry Clin Neurosci 2004; 58: 163–7
   PubMed Web of Science ®Google Scholar
• Leibowitz S, Alexander J. Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol Psychiatry 1998; 44: 851–64
   PubMed Web of Science ®Google Scholar
• Henderson D, Louie P, Koul P, Maney L, Daley T, Nguyen D. Modafinil-associated weight loss in a clozapine-treated schizoaffective disorder patient. Ann Clin Psychiatry 2005; 17: 95–7
   PubMedGoogle Scholar
• Makris A, Rush C, Frederich R, Kelly T. Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity. Appetite 2004; 42: 185–95
   PubMed Web of Science ®Google Scholar
• Greenhill L, Biederman J, Boellner S, et al. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45: 503–11
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Pashinian A, Levi A, Weizman R, Weizman A. The effects of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenic patients. Int Clin Psychopharmacol 2005; 20: 101–3
   PubMed Web of Science ®Google Scholar
• Lopez-Mato A, Rovner J, Illa G, Vieitez A, Boullossa O. Randomized, open-label study on the use of ranitidine at different doses for the management of weight gain associated with olanzapine administration. Vertex 2003; 14: 85–96
   PubMedGoogle Scholar
• Ettinger M, Littlejohn T, Schwartz S, et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults. JAMA 2003; 289: 1763–4
   PubMed Web of Science ®Google Scholar
• Norgren S, Danielsson P, Jurold R, Lotborn M, Marcus C. Orlistat treatment in obese prepubertal children: a pilot study. Acta Pediatr 2003; 92: 666–70
   PubMed Web of Science ®Google Scholar
• Azar S, Zantout M. Diabetic ketoacidosis associated with orlistat treatment. Diabetes Care 2001; 25: 602
   Google Scholar
• Birkenfeld A, Schroeder C, Pischon T, et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients. Clin Auton Res 2005; 15: 200–6
   PubMed Web of Science ®Google Scholar
• Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma A. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes 2005; 29: 509–16
   Web of Science ®Google Scholar
• Cordeiro Vallada H. Sibutramine-induced mania episode in a bipolar patient. Int J Neuropsychopharmacol 2002; 5: 283–4
   PubMed Web of Science ®Google Scholar
• Towbin K. Gaining: pediatric patients and use of atypical antipsychotics. Am J Psychiatry 2006; 163: 1034–6
   Web of Science ®Google Scholar
• Lacher M, Hermanns-Clausen M, Haeffner K, Brandis M, Pohl M. Severe metformin intoxication with lactic acidosis in an adolescent. Eur J Pediatr 2005; 164: 362–5
   PubMed Web of Science ®Google Scholar
• Aarsen F, van den Akker E. Effect of topiramate on cognition in obese children. Neurology 2006; 1: 1307–8
   Google Scholar
• Correll C, Carlson H. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolsec Psychiatry 2006; 45: 771–91
   PubMed Web of Science ®Google Scholar
• Caprio S, Genel M. Confronting the epidemic of childhood obesity. JAMA 2004; 292: 2643–6
   PubMed Web of Science ®Google Scholar
• American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596–601
   PubMed Web of Science ®Google Scholar